Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Genelux Corp (GNLX) since 2023 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Genelux Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1231457.
Total stock buying since 2023: $1,249.
Total stock sales since 2023: $15,578,093.
Total stock option exercises since 2023: $252,000.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 268,000 | $0 | 790,760 | $2,065,272 | 0 | $0 |
| 2023 | 200 | $1,249 | 608,611 | $13,512,821 | 42,000 | $252,000 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-09 | 0 | $0 | 184,548 | $462,409 | 0 | $0 |
| 2024-08 | 0 | $0 | 357,182 | $754,681 | 0 | $0 |
| 2024-06 | 0 | $0 | 17,306 | $36,687 | 0 | $0 |
| 2024-05 | 268,000 | $0 | 88,971 | $314,842 | 0 | $0 |
| 2024-04 | 0 | $0 | 142,753 | $496,653 | 0 | $0 |
| 2023-12 | 0 | $0 | 54,800 | $678,115 | 0 | $0 |
| 2023-11 | 0 | $0 | 18,665 | $191,558 | 0 | $0 |
| 2023-10 | 0 | $0 | 159,365 | $3,682,731 | 10,400 | $62,400 |
| 2023-09 | 0 | $0 | 338,027 | $8,045,313 | 31,600 | $189,600 |
| 2023-08 | 0 | $0 | 37,754 | $915,104 | 0 | $0 |
| 2023-01 | 200 | $1,249 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-13 | Szalay Aladar | Sale | 33,080 | 2.57 | 84,949 |
| 2024-09-12 | Szalay Aladar | Sale | 31,777 | 2.73 | 86,719 |
| 2024-09-11 | Szalay Aladar | Sale | 31,376 | 2.62 | 82,236 |
| 2024-09-11 | Tyree James L | Sale | 1,730 | 2.60 | 4,499 |
| 2024-09-10 | Szalay Aladar | Sale | 20,384 | 2.51 | 51,184 |
| 2024-09-09 | Szalay Aladar | Sale | 23,383 | 2.70 | 63,204 |
| 2024-09-03 | Szalay Aladar | Sale | 42,818 | 2.09 | 89,618 |
| 2024-08-30 | Szalay Aladar | Sale | 142,589 | 2.17 | 309,845 |
| 2024-08-29 | Szalay Aladar | Sale | 107,045 | 1.98 | 211,949 |
| 2024-08-28 | Szalay Aladar | Sale | 15,918 | 2.05 | 32,600 |
| 2024-08-27 | Szalay Aladar | Sale | 51,630 | 2.11 | 108,887 |
| 2024-08-23 | Szalay Aladar | Sale | 40,000 | 2.29 | 91,400 |
| 2024-06-24 | Jewett Caroline (Head of Quality) | Sale | 4,961 | 2.12 | 10,517 |
| 2024-06-24 | Ryder Sean (General Counsel) | Sale | 5,496 | 2.12 | 11,651 |
| 2024-06-24 | Yu Yong (VP, Clinical Trial Operations) | Sale | 6,849 | 2.12 | 14,519 |
| 2024-05-29 | Zak Lourie S. (Chief Financial Officer) | Buy | 31,250 | .00 | 0 |
| 2024-05-29 | Smalling Ralph (Head of Regulatory) | Buy | 1,250 | .00 | 0 |
| 2024-05-29 | Thomas John | Buy | 2,500 | .00 | 0 |
| 2024-05-29 | Zindrick Thomas (President and CEO) | Buy | 200,000 | .00 | 0 |
| 2024-05-29 | Mirabelli Mary | Buy | 8,000 | .00 | 0 |
| 2024-05-29 | Ryder Sean (General Counsel) | Buy | 10,000 | .00 | 0 |
| 2024-05-29 | Yu Yong (VP, Clinical Trial Operations) | Buy | 2,500 | .00 | 0 |
| 2024-05-29 | Smither John W | Buy | 6,250 | .00 | 0 |
| 2024-05-29 | Tyree James L | Buy | 6,250 | .00 | 0 |
| 2024-05-15 | Szalay Aladar | Sale | 17,094 | 3.66 | 62,632 |
| 2024-05-14 | Szalay Aladar | Sale | 15,426 | 3.58 | 55,271 |
| 2024-05-13 | Szalay Aladar | Sale | 3,446 | 3.62 | 12,477 |
| 2024-05-08 | Szalay Aladar | Sale | 13,919 | 3.82 | 53,184 |
| 2024-05-07 | Szalay Aladar | Sale | 6,025 | 3.67 | 22,111 |
| 2024-05-01 | Szalay Aladar | Sale | 33,061 | 3.30 | 109,167 |
| 2024-04-30 | Szalay Aladar | Sale | 20,535 | 3.12 | 63,987 |
| 2024-04-29 | Szalay Aladar | Sale | 6,403 | 3.25 | 20,790 |
| 2024-04-24 | Szalay Aladar | Sale | 8,064 | 3.50 | 28,248 |
| 2024-04-23 | Szalay Aladar | Sale | 22,000 | 3.49 | 76,802 |
| 2024-04-22 | Szalay Aladar | Sale | 14,331 | 3.53 | 50,602 |
| 2024-04-17 | Szalay Aladar | Sale | 22,737 | 3.71 | 84,422 |
| 2024-04-16 | Szalay Aladar | Sale | 48,683 | 3.53 | 171,802 |
| 2023-12-13 | Thomas John (Director) | Sale | 9,000 | 13.58 | 122,193 |
| 2023-12-13 | Tyree James L (Director) | Sale | 9,000 | 13.32 | 119,916 |
| 2023-12-07 | Yu Yong (VP, Clinical Trial Operations) | Sale | 36,800 | 11.85 | 436,006 |
| 2023-11-21 | Yu Yong (VP, Clinical Trial Operations) | Sale | 18,665 | 10.26 | 191,558 |
| 2023-10-25 | Szalay Aladar (10% Owner) | Sale | 5,704 | 19.40 | 110,640 |
| 2023-10-24 | Yu Yong (VP, Clinical Trial Operations) | Sale | 5,200 | 19.11 | 99,351 |
| 2023-10-24 | Yu Yong (VP, Clinical Trial Operations) | Option Ex | 5,200 | 6.00 | 31,200 |
| 2023-10-23 | Szalay Aladar (10% Owner) | Sale | 49,987 | 19.97 | 998,390 |
| 2023-10-16 | Thomas John (Director) | Sale | 3,333 | 20.90 | 69,669 |
| 2023-10-10 | Yu Yong (VP, Clinical Trial Operations) | Sale | 5,200 | 22.42 | 116,594 |
| 2023-10-10 | Yu Yong (VP, Clinical Trial Operations) | Option Ex | 5,200 | 6.00 | 31,200 |
| 2023-10-05 | Szalay Aladar (10% Owner) | Sale | 14,251 | 25.18 | 358,825 |
| 2023-10-03 | Szalay Aladar (10% Owner) | Sale | 75,690 | 25.49 | 1,929,262 |
| 2023-09-28 | Szalay Aladar (10% Owner) | Sale | 2,289 | 24.12 | 55,210 |
| 2023-09-27 | Szalay Aladar (10% Owner) | Sale | 11,257 | 24.47 | 275,458 |
| 2023-09-26 | Szalay Aladar (10% Owner) | Sale | 29,805 | 23.67 | 705,484 |
| 2023-09-26 | Yu Yong (VP, Clinical Trial Operations) | Sale | 5,200 | 23.51 | 122,231 |
| 2023-09-26 | Yu Yong (VP, Clinical Trial Operations) | Option Ex | 5,200 | 6.00 | 31,200 |
| 2023-09-25 | Szalay Aladar (10% Owner) | Sale | 12,458 | 26.25 | 326,960 |
| 2023-09-22 | Szalay Aladar (10% Owner) | Sale | 9,042 | 27.32 | 247,036 |
| 2023-09-21 | Szalay Aladar (10% Owner) | Sale | 7,549 | 28.35 | 214,036 |
| 2023-09-20 | Ryder Sean (General Counsel) | Sale | 10,000 | 30.00 | 300,000 |
| 2023-09-20 | Ryder Sean (General Counsel) | Option Ex | 10,000 | 6.00 | 60,000 |
| 2023-09-20 | Yu Yong (VP, Clinical Trial Operations) | Sale | 6,000 | 27.96 | 167,784 |
| 2023-09-20 | Yu Yong (VP, Clinical Trial Operations) | Option Ex | 6,000 | 6.00 | 36,000 |
| 2023-09-19 | Szalay Aladar (10% Owner) | Sale | 32,167 | 26.68 | 858,376 |
| 2023-09-18 | Thomas John (Director) | Sale | 3,334 | 24.99 | 83,316 |
| 2023-09-18 | Szalay Aladar (10% Owner) | Sale | 30,292 | 23.69 | 717,526 |
| 2023-09-15 | Thomas John (Director) | Sale | 3,333 | 22.02 | 73,409 |
| 2023-09-15 | Yu Yong (VP, Clinical Trial Operations) | Sale | 10,400 | 21.93 | 228,020 |
| 2023-09-15 | Yu Yong (VP, Clinical Trial Operations) | Option Ex | 10,400 | 6.00 | 62,400 |
| 2023-09-14 | Szalay Aladar (10% Owner) | Sale | 25,276 | 22.04 | 557,133 |
| 2023-09-13 | Szalay Aladar (10% Owner) | Sale | 19,032 | 21.79 | 414,612 |
| 2023-09-13 | Yu Yong (VP, Clinical Trial Operations) | Sale | 29,800 | 21.14 | 629,942 |
| 2023-09-13 | Smither John W (Director) | Sale | 900 | 20.78 | 18,702 |
| 2023-09-12 | Szalay Aladar (10% Owner) | Sale | 20,265 | 22.13 | 448,464 |
| 2023-09-11 | Szalay Aladar (10% Owner) | Sale | 32,351 | 21.97 | 710,719 |
| 2023-09-08 | Szalay Aladar (10% Owner) | Sale | 24,831 | 23.48 | 583,106 |
| 2023-09-07 | Szalay Aladar (10% Owner) | Sale | 12,446 | 24.73 | 307,789 |
| 2023-08-30 | Yu Yong (VP, Clinical Trial Operations) | Sale | 19,800 | 24.70 | 489,060 |
| 2023-08-18 | Smalling Ralph (Head of Regulatory) | Sale | 935 | 23.73 | 22,187 |
| 2023-08-18 | Jewett Caroline (Head of Quality) | Sale | 515 | 23.73 | 12,220 |
| 2023-08-18 | Samuelson Doug (Chief Financial Officer) | Sale | 1,297 | 23.73 | 30,777 |
| 2023-08-18 | Cappello Joseph (VP, Pharmaceutical Development) | Sale | 3,265 | 23.73 | 77,478 |
| 2023-08-18 | Zindrick Thomas (President and CEO) | Sale | 8,349 | 23.73 | 198,121 |
| 2023-08-18 | Ryder Sean (General Counsel) | Sale | 328 | 23.73 | 7,783 |
| 2023-08-18 | Yu Yong (VP, Clinical Trial Operations) | Sale | 3,265 | 23.73 | 77,478 |
| 2023-01-26 | Zhang Qian (Associate VP, Research) | Buy | 200 | 6.25 | 1,249 |
Insider trading activities including stock purchases, stock sales, and option exercises of GNLX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Genelux Corp (symbol GNLX, CIK number 1231457) see the Securities and Exchange Commission (SEC) website.